Yes. The freeze–thaw process can reduce cell viability, and some damage becomes detectable hours after thawing. The change depends on cell type, freezing formulation, thawing procedure, holding conditions, and test. In one laboratory study of human bone-marrow mesenchymal stromal cells (MSCs) from three donors, viability was 98.4–99.2% before freezing and 88.4–95.8% at 4 hours after thawing. These are results from one protocol, not an expected loss for every cell product PMC7734731.
The examples below mainly concern MSCs. They do not establish a universal thawing temperature, acceptable viability percentage, or clinical success rate. Fresh-versus-thawed comparisons also measure the combined effects of freezing, storage, thawing, and subsequent handling—not thawing alone PMC6883667.

How much does viability fall after thawing?
There is no single percentage loss. A 2019 systematic review found immediate post-thaw viability of about 50–100% across 37 bone-marrow MSC studies. Sixteen reported no change and ten reported significantly lower viability. The review included human and animal cells, different protocols, and different comparators. Its overall range is not a human clinical reference range PMC6883667.
In the three-donor human study, researchers froze passage-4 bone-marrow MSCs in 90% fetal bovine serum and 10% dimethyl sulfoxide (DMSO), thawed them at 40°C for 1 minute, then diluted and washed them. They measured viability using 7-AAD flow cytometry immediately after thawing and after further incubation in culture PMC7734731.
| Measurement time | Donor line M4 | Donor line M6 | Donor line M7 |
|---|---|---|---|
| Fresh, before freezing | 99.1% | 99.2% | 98.4% |
| 2 hours after thawing | 88.8% | 92.1% | 92.8% |
| 4 hours after thawing | 88.4% | 95.8% | 90.7% |
| 24 hours after thawing in culture | 93.1% | 97.6% | 94.3% |
Immediately after thawing, only one of the three lines had a statistically significant decrease from fresh cells; all three did at 2 and 4 hours. Statistical significance does not, by itself, establish a clinically meaningful treatment effect PMC7734731.
The authors explicitly state that this serum-containing freezing medium is not acceptable for human infusion. The experiment explains laboratory cell behaviour; it is not a preparation guide for treatment.
Why does the freeze–thaw process damage cells?
Ice formation and changes in solute concentration can injure cells during freezing and warming. Cryoprotectants such as DMSO reduce freezing injury, but exposure conditions and osmotic changes during their removal also matter. DMSO can contribute to infusion reactions, a separate issue from the percentage of cells surviving a laboratory test PMC8474714.
The cited MSC protocols used controlled, rapid warming followed by specified dilution or washing. These are protocol-specific observations, not instructions to thaw every product at 37–40°C or to wash every preparation. Clinical preparation must follow the exact product’s validated instructions, including any holding-time limits PMC7734731PMC8474714.
Can viability drop several hours later?
Yes. An immediate test may miss delayed injury. In the three-donor study, Annexin V testing showed increased apoptosis, a form of programmed cell death, after thawing. Testing only immediately after warming would have missed the viability decrease at 2–4 hours. Only five studies in the 2019 review assessed viability beyond the immediate post-thaw point PMC7734731PMC6883667.
Viability percentages partly recovered by 24 hours in culture, but metabolic activity and adhesion remained below fresh-cell levels. A higher later percentage does not establish that the original viable cell count or all functions have been restored. Overnight culture results cannot replace a test at the actual administration time PMC7734731.
What changes post-thaw survival?
Holding solution and dilution
In a study of human adipose-derived MSCs, protein-free thawing solutions caused up to 50% cell loss. Saline with 2% human serum albumin performed similarly to culture medium during thawing. After reconstitution at 5 million cells per milliliter, saline maintained viability above 90% with no observed cell loss for at least 4 hours; culture medium and phosphate-buffered saline performed poorly after 1 hour at room temperature in that setup PMC10154666.
Dilution below 100,000 cells per milliliter in protein-free vehicles caused immediate losses exceeding 40% and viability below 80%. Albumin supplementation helped prevent thawing- and dilution-related losses in that study. These findings explain why solution composition belongs in a post-thaw report; they do not establish a universal saline or albumin recipe PMC10154666.
Freezing formulation and concentration
In a separate MSC study at 3 million cells per milliliter, immediate viability by trypan blue was 89.3%, 88.1%, and 89.3% for three formulations containing 10% DMSO, compared with 82.7% for a formulation containing 5% DMSO. These were different formulations, not a test isolating DMSO concentration alone. The result does not mean that increasing DMSO always improves survival PMC11324487.
How should you read a viability report?
Viability is the proportion of tested cells meeting a particular assay’s definition of alive. It differs from live-cell recovery: how many viable cells were recovered relative to the starting quantity. Dye-exclusion tests, flow cytometry, and apoptosis assays assess different features, so their percentages are not interchangeable PMC6883667PMC11324487.
A worked report-reading example
Consider a hypothetical sample with 100 million counted cells, of which 90 million are viable: viability is 90%. A later sample with 50 million counted cells and 45 million viable cells is also 90% viable, despite containing half as many viable cells. This is an arithmetic illustration, not a patient case or an observed laboratory result.
A result labelled “before freezing” cannot answer how many cells survived thawing. A result labelled “24 hours in culture” does not describe a preparation used immediately after thawing. Ask for the relevant sampling time, total recovered count, viable count, and method rather than comparing percentages alone.
- Which cell type, source, batch, and starting quantity were tested?
- Was testing before freezing, immediately after thawing, or after a stated holding period?
- Which assay was used, and was the same method used for the comparison?
- What were the freezing formulation, thawing procedure, dilution, holding solution, temperature, and duration?
- Does the report state both viability and the number of viable cells recovered?
For cells from a cell processing center, request batch-specific results rather than relying on a general processing description. During the stem cell treatment process in Japan, clarify whether a quoted count refers to the pre-freeze sample or the final preparation.
Does high viability mean the cells will work?
No. In the three-donor study, post-thaw proliferation rates were preserved, but colony-forming ability decreased in two lines and differentiation effects varied by donor. Viability is not a substitute for measuring relevant functions. FDA guidance states that potency measurements are designed for particular cellular and gene therapy products; it does not prescribe one universal assay or product-release cutoff PMC7734731Potency tests cellular and gene therapy products.
For treatment decisions, separate laboratory survival from clinical benefit and regulatory status. FDA approvals apply to specific listed products in the United States, not to a viability percentage Approved cellular and gene therapy products.
In Japan, provision-plan submission and committee review under the Act on the Safety of Regenerative Medicine are distinct from product marketing authorization. A filing number alone proves neither post-thaw viability nor treatment effectiveness En0003. When checking Japan’s regenerative medicine registration and compliance, ask separately for the batch report and the evidence supporting the proposed treatment.
Bottom line
Thawing can affect viability, but the loss is not fixed and an immediate reading may miss delayed injury. Compare fresh and post-thaw results using matched methods and documented handling conditions. The most useful report gives both the viable cell count and viability at the time relevant to use—not just a headline percentage PMC7734731PMC11324487.
Have questions about a quoted cell count?
Contact the patient support team to organize questions about sampling time, testing method, and records to request from the clinic. Laboratory interpretation and treatment decisions belong to qualified professionals.
General information only, not personal medical advice or instructions for preparing cells for administration. No treatment outcome is guaranteed.




